STABLECOIN DEVELOPMENT CORPORATION Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2018-11-14: Study NCT03861728; Company role Collaborator; Phase Not applicable; Status Terminated.
- 2016-10: Study NCT02938078; Company role Collaborator; Phase Not applicable; Status Terminated.
- 2015-05: Study NCT02455895; Company role Lead sponsor; Phase Not applicable; Status Unknown.
- 2014-09: Study NCT02130518; Company role Lead sponsor; Phase Phase 2; Status Unknown.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2018-11-14 | NCT03861728 Viral Conjunctivitis Treatment Study | Collaborator Lead: University of Miami | Not applicable | Terminated Results posted | Viral Conjunctivitis | 11 | 2020-02-08 |
| 2016-10 | NCT02938078 Ocular Comfort and Inflammation in Lid Hygiene Therapy | Collaborator Lead: Minnesota Eye Consultants, P.A. | Not applicable | Terminated | Blepharitis | 14 | 2018-08-24 |
| 2015-05 | NCT02455895 Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora | Lead sponsor | Not applicable | Unknown | Sebaceous Gland Diseases; Blepharitis | 100 | 2016-05 |
| 2014-09 | NCT02130518 Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency | Lead sponsor | Phase 2 | Unknown | Urinary Catheter Blockage and Encrustation | 140 | 2016-01 |
| 2013-06 | NCT01877694 Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis | Lead sponsor | Phase 2 | Completed | Bacterial Conjunctivitis | 217 | 2015-01 |
| 2012-08 | NCT01670032 Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo | Lead sponsor | Phase 2, Phase 3 | Completed | Impetigo | 328 | 2013-08 |
| 2012-05 | NCT01532336 Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis | Lead sponsor | Phase 2 | Completed | Adenoviral Conjunctivitis | 500 | 2014-08 |
| 2010-11 | NCT01243125 Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation | Lead sponsor | Phase 2 | Completed | Urinary Catheter Blockage and Encrustation | 67 | 2013-08 |
| 2009-08 | NCT01367314 Safety and Efficacy of Topical NVC-422 Gel in Impetigo | Lead sponsor | Phase 2 | Completed | Impetigo | 129 | 2010-12 |
| 2008-10 | NCT00781339 Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients | Lead sponsor | Phase 2 | Completed | Asymptomatic Bacteriuria | 20 | 2010-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FORUM MARKETS Inc (FRMM) | United States | $0.069B | -0.13 |
| ZeroStack Corp. (ZSTK) | $0.069B | -0.04 | |
| Exodus Movement, Inc. (EXOD) | United States | $0.073B | 2.92 |
| SkyAI, Inc. (SKYA) | United States | $0.081B | |
| Empery Digital Inc. (EMPD) | United States | $0.082B | -0.36 |
| BTCS Inc. (BTCS) | United States | $0.085B | -0.45 |
| Marygold Companies, Inc. (MGLD) | United States | $0.044B | -11.63 |
| AVAX ONE TECHNOLOGY LTD. (AVX) | $0.040B | -0.36 | |
| FG Nexus Inc. (FGNX) | United States | $0.039B | -429.84 |
| Big Digital Energy, Inc. (BGDE) | $0.035B |